MedTrace Logo

Complement C5 mAb in the Treatment of Anti-GBM Disease

NCT06513338 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-12-05

No results posted yet for this study

Summary

Anti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease. Complement has been shown to participate in the pathogenesis of anti-GBM disease. This study aims to the investigate the therapeutic effects and safety of C5 monoclonal antibody in the treatment of anti-GBM disease.

Conditions

Interventions

DRUG

Eculizumab

eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for 8 weeks

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Zhao Cui · PKUFH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2025-11-03
Completion
2025-11-03

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06513338 on ClinicalTrials.gov